Search icon
Learn, Analyse & Invest
only with
Orca logoArrow icon
+91
Download Orca
orca play storeorca apple store
To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Morepen Laboratories Ltd.

Morepen Laboratories

0.00

0.00 (0.00)%

NSE

BSE

EX-DatePurpose
28 04 2021 Inter-alia, to consider and approve proposals for raising of funds, through one or more modes including further public offer/ right issue/ preferential issue of equity shares/ warrants/ fully or partly convertible instruments to public, investors, indian or foreign institution(s), body corporate including overseas corporate body(ies), NRI, foreign portfolio investor(s), promoters, promoter group and/or other entities, subject to such regulatory, statutory/ other approvals, as may be required.
04 05 2021 Audited Results
27 07 2021 Quarterly Results
11 11 2021 Quarterly Results
08 02 2022 Quarterly Results Inter alia, to consider and approve: (2) Variation/alteration of preference shareholders? rights, by converting said unlisted preference shares into Compulsorily Convertible Preference Shares and issuance of Equity Shares arising on conversion thereof, subject to the approval of preference shareholders, equity shareholders and such other regulatory, statutory authority(ies), as may be required.
05 05 2022 Audited Results
29 07 2022 Quarterly Results
10 11 2022 Quarterly Results
13 02 2023 Quarterly Results
16 05 2023 Audited Results
05 08 2023 Quarterly Results
02 11 2023 Quarterly Results
31 01 2024 Quarterly Results
22 02 2024 Inter alia, consider and approve the following matters: 1. To evaluate proposals for fund raising by the Company, by way of, inter-alia, issue of securities including equity shares or any other equity linked instruments or securities including nonconvertible debt instruments along with warrants and convertible securities other than warrants or any other eligible securities by way of, inter-alia, a preferential allotment or a private placement (including one or more qualified institutions placements or further public issue of equity, in accordance with the applicable provisions of the Companies Act, 2013 and its rules made thereunder and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or through any other permissible mode, in such manner, and on such terms and conditions as may be deemed appropriate by the Board of Directors, including committee thereof, in its absolute discretion, subject to the receipt of necessary approvals, including the approval of the members of the Company at general meetings or through postal ballot and such other parties including regulatory and statutory approvals as may be required; 2. The notice of Extra-Ordinary General Meeting of the Company or Postal Ballot Notice along with explanatory statement thereto, inter-alia, for seeking approval of the members of the Company in relation to the above fund-raising proposal.
11 11 2024 Quarterly Results
06 02 2025 Quarterly Results
12 05 2025 Audited Results & Quarterly Results & Final Dividend
06 08 2025 Quarterly Results

News

01-APR-2025

Morepen Laboratories secures Loratadine approval for export to China

This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets

09:50 AM
09-JAN-2025

Morepen Laboratories incorporates subsidiary company

The objective of incorporation of the subsidiary company is to enhance the capabilities, expansion of business operations and strategic alignment

09:44 AM
09-SEP-2025

Morepen Laboratories’ arm executes JV agreement with Bimedical FZE

The proposed JV company will carry on the business of manufacturing, trading and selling of medical devices related products

09:37 AM
11-DEC-2024

Morepen Laboratories’ arm introduces weight management program ‘LightLife’

The program offers Pre-meal Nutrition Drinks and On-the-Go Meal, providing easy, convenient solutions that match your fast-paced lifestyle

12:58 PM
13-MAY-2025

Morepen Laboratories reports 29% fall in Q4 consolidated net profit

The total consolidated income of the company increased by 10.10% at Rs 470.46 crore for Q4FY25

12:29 PM
15-JAN-2025

Morepen Laboratories to hive off medical devices business

The BTA will be executed in due course

11:30 AM
18-MAR-2023

Morepen Laboratories incorporates wholly owned subsidiary

The company has incorporated a WOS on March 17, 2023

11:05 AM
18-MAR-2025

Morepen Laboratories launches Empamore

Morepen manufactures Empagliflozin in its USFDA-approved facilities and already has European DMF

09:29 AM
19-FEB-2025

Morepen Laboratories’ arm gets nod to form new subsidiary company

The proposed new company will operate in the pharmaceutical sector, specializing in the ’Online Retail Pharmacy’ business

02:51 PM
19-JUN-2025

Morepen Laboratories incorporates wholly owned subsidiary in Dubai

The said WOS has been incorporated for trading in pharmaceuticals/ medicines (outside UAE)

10:52 AM
19-MAR-2025

Morepen Laboratories to transfer Medical Devices Business

The Medical Devices Business will be transferred to Morepen Medtech

02:46 PM
20-MAR-2025

Morepen Laboratories incorporates step-down subsidiary

Quick Med is a subsidiary of Dr. Morepen

06:02 PM
23-JUL-2025

Morepen Laboratories incorporates step-down subsidiary in Dubai

The newly formed company will engage in the sales & marketing of medical devices’ products in the international market including Dubai, UAE, and others

11:08 AM
25-JUL-2025

Morepen Laboratories’ arm to incorporate wholly owned subsidiary

The company will indirectly hold 60% of the equity shares in the proposed new step-down subsidiary through MML

05:50 PM
27-MAR-2023

USFDA conducts inspection of Morepen Laboratories’ API manufacturing facility at Baddi

The facility has been cleared by USFDA on March 24, 2023 without any adverse observation

02:08 PM
29-APR-2025

Morepen Laboratories to launch new drug for Fatty Liver

The company has received clearance from Subject Expert Committee of CDSCO to conduct Bioequivalence studies for Resmetirom 60 mg, 80 mg and 100 mg tablets

12:50 PM
29-APR-2025

Morepen Laboratories gets nod to incorporate wholly owned subsidiary in Dubai

The Finance Committee of the Board of Directors of the Company, at its meeting held on April 28, 2025 has approved the same

10:09 AM
Enrich money logo